Alopecia Market – By Disease Type, By Treatment Type, By Gender, By Sales Channel, By End Use - Global Forecast, 2024 – 2032

Alopecia Market Size

The alopecia market size was valued at around USD 8.7 billion in 2023 and is estimated to grow at 8.1% CAGR from 2024 to 2032. The increasing prevalence of alopecia, coupled with growing awareness about treatment options, is driving the growth of the market.
 

The rise in alopecia cases is fueling market growth as more individuals seek effective treatments. Factors contributing to the increasing prevalence include genetic predisposition, hormonal imbalances, autoimmune disorders, and environmental stressors. Additionally, lifestyle factors such as poor nutrition and stress are exacerbating hair loss conditions. For example, according to the National Alopecia Areata Foundation, approximately 6.8 million people in the U.S. alone are affected by alopecia areata, with numbers rising globally. This growing patient population is driving demand for treatments, including pharmaceuticals and advanced hair restoration techniques.
 

Moreover, increasing awareness of alopecia treatment options is further boosting market growth, as more individuals seek solutions for hair loss. Advancements in treatments such as pharmaceuticals, laser therapy devices, and hair transplants, combined with greater visibility through advertising and social media, have made treatments more accessible. This heightened awareness encourages more people to pursue available therapies, increasing market demand.
 

Alopecia is a medical condition characterized by partial or complete hair loss from the scalp, face, or other parts of the body. It can result from various factors, including genetics, autoimmune disorders, hormonal changes, or underlying medical conditions. The condition can manifest in different forms, such as localized or diffuse hair loss, and it may be either temporary or permanent.
 

Alopecia Market Trends

Technological advancements in alopecia treatments have revolutionized the market, offering more effective and diverse solutions for hair loss. These innovations span pharmaceuticals, devices, and therapies, contributing to the rapid growth of the alopecia treatment market.

• New drugs, particularly JAK inhibitors, have shown significant promise in treating alopecia areata by targeting the immune pathways responsible for hair loss. Additionally, research into biologics has opened the door for more targeted therapies.
   
• Platelet-Rich Plasma (PRP) therapy has also emerged as a cutting-edge treatment, where a patient's own blood plasma, rich in growth factors, is injected into the scalp to encourage hair regeneration. This therapy is gaining popularity due to its natural, minimally invasive approach.
   
• Moreover, ongoing research into stem cell therapies aims to stimulate hair follicle regeneration. Although still in the experimental phase, stem cell-based treatments have the potential to reshape the future of alopecia care. These technological advancements have expanded treatment options, improved patient outcomes, and driven significant growth in the market.
   

Alopecia Market Analysis

Based on disease type, the alopecia market is classified into androgenetic alopecia, alopecia areata, and other disease types. The androgenetic alopecia segment generated the highest revenue of USD 4.8 billion in 2023.
 

• Androgenetic alopecia, also known as male or female pattern baldness, affects a large portion of the population, particularly men. According to the National Institutes of Health, androgenetic alopecia impacts nearly 30-50% of men by the age of 50. Its widespread prevalence drives demand for effective treatments, making this segment dominant in the market.
   
• Furthermore, a variety of well-established treatment solutions are available for androgenetic alopecia, including topical medications like minoxidil, oral drugs like finasteride, and advanced procedures such as hair transplants. These clinically proven options result in higher patient adoption rates, further contributing to the segment's growth.
   

Based on treatment type, the alopecia market is categorized into pharmaceuticals, devices, and other treatments. The pharmaceuticals segment dominated the market by obtaining 48.8% of market share in 2023.
 

• Pharmaceuticals, including both topical treatments and oral medications, are widely accepted and recommended as first-line treatments for various forms of alopecia. These solutions are non-invasive, easy to use, and have proven efficacy in promoting hair regrowth, making them the most accessible and preferred treatment option.
   
• Additionally, pharmaceutical treatments are generally more affordable compared to devices and other therapies, leading to higher adoption rates. Many of these drugs are FDA-approved and supported by substantial clinical research, ensuring their safety and effectiveness, further driving their adoption in the market.
   

Based on gender, the alopecia market is categorized into male and female. The male segment is anticipated to dominate the market by obtaining USD 11.6 billion in 2032.
 

• Androgenetic alopecia, commonly known as male pattern baldness, is far more prevalent among men than women. Studies suggest that around 50% of men experience noticeable hair loss by the age of 50, significantly contributing to the market demand for alopecia treatments.
   
• Furthermore, hair loss in men typically starts at an earlier age and progresses more rapidly compared to women, which drives men to seek treatments more frequently and at an earlier stage, further boosting the dominance of the male segment.
   

Based on sales channel, the alopecia market is classified into prescription and OTC. The prescription segment is anticipated to grow at the fastest pace of CAGR 8.3% during the forecast period.
 

• Prescription treatments for alopecia, such as finasteride or certain corticosteroids, are often more potent and specifically targeted, offering better outcomes than over-the-counter (OTC) options. This encourages patients to seek medical consultation for stronger treatment plans.
   
• Additionally, certain alopecia conditions, such as androgenetic alopecia or severe alopecia areata, often require stronger, dermatologist-prescribed medications that are not available OTC, leading to higher demand for prescription-based treatments.
   

Based on end-use, the alopecia market is classified into dermatology clinics, homecare settings, and other end-users. The dermatology clinics segment generated the highest revenue of USD 4.6 billion in 2023.
 

• Dermatology clinics offer professional expertise in diagnosing and treating various forms of alopecia. They also provide access to advanced treatments such as laser therapies, prescription medications, and hair restoration procedures, which are typically unavailable in home care settings.
   
• Additionally, clinical treatments administered by dermatologists, such as PRP therapy, microneedling, and specialized topical or oral medications, are perceived to deliver more effective and long-lasting results, encouraging more patients to seek treatments at these clinics.
   

North America alopecia market accounted for USD 3.2 billion market revenue in 2023 and is anticipated to grow at CAGR of 7.7% between 2024 to 2032 period.
 

• The prevalence of alopecia, particularly androgenetic alopecia, is significant in North America, with a large portion of the population experiencing hair loss. This high incidence drives demand for effective treatments and contributes to market growth.
   
• Additionally, North America boasts advanced healthcare infrastructure and access to cutting-edge treatments, including pharmaceuticals, laser therapies, and surgical options. This infrastructure supports the market by facilitating the availability and adoption of innovative solutions.
   

The U.S. held a dominant position in the alopecia market, with a revenue of USD 3.1 billion in 2023.
 

• The U.S. has a robust market for hair restoration technologies, with high demand for prescription medications, advanced devices, and surgical options like hair transplants. The presence of major companies and high consumer spending power boost the market.
   
• Moreover, growing awareness about alopecia treatments and increasing societal acceptance of cosmetic interventions contribute to higher adoption rates. This trend is reinforced by extensive marketing and educational campaigns.
   

UK alopecia market is anticipated to witness substantial growth during 2024 to 2032 period.
 

• In the UK, improved diagnostic services for alopecia are driving market growth. Educational initiatives and accessible diagnostic tools facilitate early detection and treatment, leading to increased market demand.
   
• Additionally, the UK's healthcare system and insurance policies are increasingly supportive of hair loss treatments, including coverage for certain prescription medications. This support enhances accessibility and encourages market growth.
   

Japan holds a dominant position in the Asia Pacific alopecia market.
 

• Japan has a rapidly aging population, with a significant proportion experiencing hair loss due to age. This demographic shift drives the demand for effective alopecia treatments tailored to older individuals.
   
• Moreover, there is a growing trend toward cosmetic procedures and personal grooming in Japan. This cultural shift towards enhancing physical appearance boosts demand for alopecia treatments, including both pharmaceutical and non-pharmaceutical solutions.
   

Alopecia Market Share

The alopecia industry is fragmented, with various large multinationals and small to mid-sized companies competing in the market. The development and launch of novel treatments with improved efficiency and cost-effectiveness are key strategies for pharmaceutical and device manufacturers, driving competition and innovation within the industry. This focus on innovation aims to address evolving clinical needs and enhance patient outcomes, positioning companies to gain considerable market share while meeting the growing demand for advanced alopecia-related products.
 

Alopecia Market Companies

Some of the eminent market participants operating in the alopecia industry include:

• Apira Science, Inc. (iGROW Laser)
• Aurobindo Pharma
• Bosley – Hair Restoration & Transplant
• Cipla
• Curallux, LLC
• Dr. Reddy’s Laboratories Ltd.
• Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
• Johnson & Johnson Services, Inc.
• Lexington International., LLC
• Merck KGaA
• Pfizer Inc.
• REVIAN, Inc.
• Smart Graft
• Sun Pharmaceuticals Industries Ltd.
• Theradome Inc.
   

Alopecia Industry News:

• In July 2024, Sun Pharmaceutical Industries Limited announced that the U.S. Food and Drug Administration (FDA) approved their LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia. This approval is expected to increase the company’s reputation in the market, along with revenue and expansion of their product portfolio.
   
• In June 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved their LITFULO (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata. This approval enhances Pfizer's competitiveness in the alopecia treatment market, particularly as it provides a novel option for a demographic that previously had limited treatment choices.
   

The alopecia market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Disease Type

• Androgenetic alopecia
• Alopecia areata
• Other disease types 

Market, By Treatment Type

• Pharmaceuticals      
  • Topical
  • Oral
• Devices        
  • Laser cap
  • Laser comb
  • Laser helmet
• Other treatments

By Gender   

• Male   
• Female         

By Sales Channel 

• Prescription
• OTC   

By End Use

• Dermatology clinics 
• Homecare settings   
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa